Emilio Bouza: Clinical Trials

3 completed, 2 unknown. 1 Not applicable.

By phase and status

Phase	Trials	Status
Not applicable	1	Completed 1

Follow Emilio Bouza: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies Retrospective, Prospective - Clostridium Difficile Infection		Unknown	Emilio Bouza	513	2019-12-01	2020-07-29
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients Ceftolozane/tazobactam, imipenem- relebactam - Ceftolozane/Tazobactam, Imipenem/Relebactam		Unknown	Emilio Bouza	1005	2019-11-01	2019-12-12
PCR Technique to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples Thoracic Surgery		Completed	Emilio Bouza	200	2015-07-01	2016-10-14
CMV Intensive Care Units CMV Infection		Completed	Emilio Bouza	150	2012-10-01	2014-12-24
Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign Telephone call - Sepsis	Not applicable	Completed	Emilio Bouza	300	2012-08-01	2014-12-30

Conditions studied

Clostridium Infections (1)  ·  Cytomegalovirus Infections (1)  ·  Neoplasms (1)  ·  Sepsis (1)

Interventions

Longitudinal Studies (1)  ·  Retrospective Studies (1)  ·  ceftolozane, tazobactam drug combination (1)  ·  imipenem, cilastatin and relebactam (1)

Countries

Spain (5)

Top investigators

Almudena Burillo, MD, PhD (1)  ·  Eleonora Bunsow, MD, PhD (1)  ·  Emilio Bouza Santiago, MD, PhD (1)

Results publications

PMID 26426609, PMID 30586363, PMID 31668380